Companies · Biotechnology

Electrochemical Oxygen Concepts Inc

SAN ANTONIO · Biotechnology

Diligence memoA one-page analyst read on Electrochemical Oxygen Concepts Inc — recommendation, valuation, rhythm, risks.
$21.4M
Total raised · real
11
Rounds
0.7×
Latest step-up
Top 32%
Sector rank · raised
Series A
Latest stage · inferred · Wed Sep 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Electrochemical Oxygen Concepts Inc looks under-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.10× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
At-risk
  • Last raise 3.8 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Electrochemical Oxygen Concepts Inc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
17.6 yr record
Peak capital year was 2011 with $16.8M across 5 filings.
Market position
ahead of 69% of Biotechnology peers
Capital scale is ahead of 69% of Biotechnology peers; modeled value is above 9% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2011: $16.8M across 5 filings.
  • Largest single filing was $8.7M on 2018-05-03.
  • Filing rows sum to $40.7M, while canonical raised total is $21.4M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Electrochemical Oxygen Concepts Inc is one of 4293 Biotechnology companies tracked from SAN ANTONIO. By capital raised it ranks mid-pack (ahead of 69% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
7
Investors (latest)
2022-09-28
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MPre-Seed · 2008-12-12 Raised $150K (real) Modeled valuation $8.3M (est)Pre-Seed2008Pre-Seed · 2009-04-01 Raised $243K (real) Modeled valuation $13M (est)Pre-Seed · 2009-04-01 Raised $733K (real) Modeled valuation $40M (est)Pre-Seed2009Pre-Seed · 2009-07-31 Raised $705K (real) Modeled valuation $39M (est)Pre-Seed · 2010-05-13 Raised $811K (real) Modeled valuation $45M (est)Pre-Seed2010Pre-Seed · 2010-05-13 Raised $990K (real) Modeled valuation $55M (est)Pre-Seed · 2010-05-13 Raised $990K (real) Modeled valuation $55M (est)Pre-Seed2010Pre-Seed · 2010-05-13 Raised $538K (real) Modeled valuation $30M (est)Seed · 2010-05-13 Raised $2.4M (real) Modeled valuation $108M (est)Seed2010Seed · 2010-05-13 Raised $2.5M (real) Modeled valuation $111M (est)Seed · 2011-08-29 Raised $3.9M (real) Modeled valuation $171M (est)Seed2011Seed · 2011-08-29 Raised $2.0M (real) Modeled valuation $89M (est)Series A · 2011-08-29 Raised $4.3M (real) Modeled valuation $155M (est)Series A2011Seed · 2011-08-29 Raised $2.4M (real) Modeled valuation $106M (est)Series A · 2011-08-29 Raised $4.3M (real) Modeled valuation $155M (est)Series A2011Series A · 2017-07-07 Raised $908K (real) Modeled valuation $33M (est)Series A · 2018-05-03 Raised $8.7M (real) Modeled valuation $315M (est)Series A2018Series A · 2019-08-19 Raised $2.3M (real) Modeled valuation $83M (est)Series A · 2020-08-19 Raised $500K (real) Modeled valuation $17M (est)Series A2020Series A · 2020-11-02 Raised $500K (real) Modeled valuation $15M (est)Series A · 2021-01-21 Raised $500K (real) Modeled valuation $14M (est)Series A2021Series A · 2022-09-28 Raised $370K (real) Modeled valuation $4.5M (est)Cumulative $41M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$150K · 2008
Pre-Seed extension$243K · 2009
Pre-Seed extension$733K · 2009
Pre-Seed extension$705K · 2009
Pre-Seed extension$811K · 2010
Pre-Seed extension$990K · 2010
Pre-Seed extension$990K · 2010
Pre-Seed extension$538K · 2010
Seed$2.4M · 2010
Seed extension$2.5M · 2010
Seed extension$3.9M · 2011
Seed extension$2.0M · 2011
Series A$4.3M · 2011
Bridge · Series A-stage$2.4M · 2011smaller follow-on
Series A extension$4.3M · 2011
Series A extension$908K · 2017
Series A extension$8.7M · 2018
Series A extension$2.3M · 2019
Series A extension$500K · 2020
Series A extension$500K · 2020
Series A extension$500K · 2021
Series A extension$370K · 2022

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$4.5M
Base estimate est.
$404K
Conservative case
$14.7M
Upside case
$1.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $8.3M · 2008-12-122008Pre-Seed · modeled $13.4M · 2009-04-01Pre-Seed · modeled $40.4M · 2009-04-01Pre-Seed · modeled $38.9M · 2009-07-31Pre-Seed · modeled $44.8M · 2010-05-13Pre-Seed · modeled $54.7M · 2010-05-13Pre-Seed · modeled $54.7M · 2010-05-13Pre-Seed · modeled $29.7M · 2010-05-13Seed · modeled $108.1M · 2010-05-13Seed · modeled $111.0M · 2010-05-13Seed · modeled $171.1M · 2011-08-29Seed · modeled $88.7M · 2011-08-29Series A · modeled $155.1M · 2011-08-29Seed · modeled $105.5M · 2011-08-29Series A · modeled $154.6M · 2011-08-29Series A · modeled $32.8M · 2017-07-07Series A · modeled $314.9M · 2018-05-03Series A · modeled $83.1M · 2019-08-19Series A · modeled $17.0M · 2020-08-19Series A · modeled $15.4M · 2020-11-02Series A · modeled $13.8M · 2021-01-21Series A · modeled $4.5M · 2022-09-282022
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
3.8 yr
Elapsed time used
3.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
8 mo
Avg between rounds
$1.6M/yr
Capital velocity
17.6 yr
On record since
2008
First round
22
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.0× above median
This company$21.4M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.1× of median
This company$370K
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$4.5M
Sector median$64.2M

Raised more than 69% of sector peers (real $). Modeled value above 9% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #280 of 303.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.3M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $216.2M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $207.1M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.5M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $189.2M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.2M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.9M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $184.0M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.4M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.4M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.4M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $169.0M (est)Electrochemical Oxygen Concepts Inc (this company) Raised $21.4M · modeled $4.5M (est)Electrochemical Oxygen Concepts Inc
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.3M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$216.2M4.87×
Adient Medical, Inc.Series A$18.2M$207.1M4.67×
Entegrion IncSeries A$22.7M$191.5M4.32×
BCD Bioscience, Inc.Series A$16.4M$189.2M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.2M4.20×
MicroByre, Inc.Series A$16.1M$185.9M4.19×
Cardiac Insight, Inc.Series A$38.1M$184.0M4.15×
Cardiac Implants LLCSeries A$13.5M$178.4M4.02×
Abintus Bio, Inc.Series A$13.7M$177.4M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.4M3.98×
Mazen Animal Health Inc.Series A$13.5M$169.0M3.81×
Electrochemical Oxygen Concepts Inc this companySeries A$21.4M$4.5M0.10×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$150K2008-12-12$833K$8.3M85%
Pre-Seed$243K2009-04-01$1.3M$13.4M85%
Pre-Seed$733K2009-04-01$4.1M$40.4M85%
Pre-Seed$705K2009-07-31$3.9M$38.9M85%
Pre-Seed$811K2010-05-13$4.5M$44.8M85%
Pre-Seed$990K2010-05-13$5.5M$54.7M85%
Pre-Seed$990K2010-05-13$5.5M$54.7M85%
Pre-Seed$538K2010-05-13$3.0M$29.7M85%
Seed$2.4M2010-05-13$12.2M$108.1M85%
Seed$2.5M2010-05-13$12.5M$111.0M85%
Seed$3.9M2011-08-29$19.3M$171.1M85%
Seed$2.0M2011-08-29$10.0M$88.7M85%
Series A$4.3M2011-08-29$19.5M$155.1M85%
Seed$2.4M2011-08-29$11.9M$105.5M85%
Series A$4.3M2011-08-29$19.4M$154.6M85%
Series A$908K2017-07-07$4.1M$32.8M90%
Series A$8.7M2018-05-03$39.6M$314.9M90%
Series A$2.3M2019-08-19$10.5M$83.1M90%
Series A$500K2020-08-19$2.3M$17.0M90%
Series A$500K2020-11-02$2.3M$15.4M90%
Series A$500K2021-01-21$2.3M$13.8M90%
Series A$370K2022-09-28$1.7M$4.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$150K2008-12-12
    • First recorded raise — entered as Pre-Seed.
  2. Pre-Seed$243K2009-04-01
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 1.6× larger than the prior — scaling up.
    • 14 investors on this round.
  3. Pre-Seed$733K2009-04-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.0× larger than the prior — scaling up.
    • 21 investors on this round.
  4. Pre-Seed$705K2009-07-31
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 19 investors on this round.
  5. Pre-Seed$811K2010-05-13
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 20 investors on this round.
  6. Pre-Seed$990K2010-05-13
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 27 investors on this round.
  7. Pre-Seed$990K2010-05-13
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 27 investors on this round.
  8. Pre-Seed$538K2010-05-13
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 12 investors on this round.
  9. Seed$2.4M2010-05-13
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.5× larger than the prior — scaling up.
    • 62 investors on this round.
  10. Seed$2.5M2010-05-13
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 65 investors on this round.
  11. Seed$3.9M2011-08-29
    • Raised 16 mo later, in step with the ~14 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
    • 43 investors on this round.
  12. Seed$2.0M2011-08-29
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.9× smaller than the prior — bridge or down round.
    • 17 investors on this round.
  13. Series A$4.3M2011-08-29
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.1× larger than the prior — scaling up.
    • 47 investors on this round.
  14. Seed$2.4M2011-08-29
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 26 investors on this round.
  15. Series A$4.3M2011-08-29
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.8× larger than the prior — scaling up.
    • 46 investors on this round.
  16. Series A$908K2017-07-07
    • Raised again after 70 mo — slower than the ~14 mo sector norm.
    • Round 4.7× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 2 investors on this round.
  17. Series A$8.7M2018-05-03
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 9.6× larger than the prior — scaling up.
    • 16 investors on this round.
  18. Series A$2.3M2019-08-19
    • Raised 16 mo later, in step with the ~14 mo sector norm.
    • Round 3.8× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  19. Series A$500K2020-08-19
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 4.6× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  20. Series A$500K2020-11-02
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  21. Series A$500K2021-01-21
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  22. Series A$370K2022-09-28
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 1.4× smaller than the prior — bridge or down round.
    • 7 investors on this round.
Intelligence
2023 ~Q2
Modeled next raise · ~8mo cadence
$370K
Modeled next size est.range $370K$592K
0.7×
Last step-up
$1.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
James Walsh2 other2022-09
Jim Walsh1 other2018-05
L. Peter Smith1 other2008-12
David J. Kazynski2008-12
Dr. Lanny Q. Geary2017-07
James W. DeYoung2008-12
Jim J. Phillips2010-05
Jim W. Phillips2017-07
Joseph Q. Moffett2017-07
Joseph W. Moffett2018-05
Lee M. Kelley2011-08
Mark Q. Niederauer2011-08
Michael C Wells2008-12
Ted M. Buchter2008-12
Registry & provenance

Electrochemical Oxygen Concepts Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1436343
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
GeneCentric Therapeutics, Inc.BiotechnologySeries A$21.6M$6.7Msame sector · same stage
Cardio Flow, Inc.BiotechnologySeries A$20.8M$2.1Msame sector · same stage
EnteroBiotix LTDBiotechnologySeries A$23.2M$4.4Msame sector · same stage
BioRestorative Therapies, Inc.BiotechnologySeries A$19.8M$4.0Msame sector · same stage
MAIA Biotechnology, Inc.BiotechnologySeries A$19.6M$3.9Msame sector · same stage
Scorpius Holdings, Inc.BiotechnologySeries A$23.6M$3.9Msame sector · same stage
Aethlon Medical IncBiotechnologySeries A$25.1M$5.7Msame sector · same stage
Xenetic Biosciences, Inc.BiotechnologySeries A$17.6M$5.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Electromedical Technologies, IncBiotechnologyPre-Seed$5.8M88%
Elektrofi, Inc.BiotechnologySeries D+$1.2B83%
Neuroelectrics, Inc.BiotechnologySeries B$611.8M83%
CytoBioscience, Inc.BiotechnologySeries B$60.7M82%
Eclipse Bioinnovations, Inc.BiotechnologySeries A$13.5M82%
Ocean Biomedical, Inc.BiotechnologySeries A$67.6M82%
Aura Biosciences, Inc.BiotechnologySeries C$2.5B82%
HeMemics Biotechnologies, Inc.BiotechnologyPre-Seed$4.2M82%
Frequently asked
How much funding has Electrochemical Oxygen Concepts Inc raised?
Electrochemical Oxygen Concepts Inc has raised approximately $21.4M in disclosed capital across 11 recorded financing rounds, aggregated from public filings.
What is Electrochemical Oxygen Concepts Inc's estimated valuation?
Provath's modeled valuation for Electrochemical Oxygen Concepts Inc is approximately $4.5M (modeled range $404K–$14.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Electrochemical Oxygen Concepts Inc at?
Electrochemical Oxygen Concepts Inc's latest modeled financing stage is Series A. Its most recent recorded round closed around Wed Sep 28.
What does Electrochemical Oxygen Concepts Inc do and where is it based?
Electrochemical Oxygen Concepts Inc operates in the Biotechnology sector, based in SAN ANTONIO.
Explore related

See where Electrochemical Oxygen Concepts Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Electrochemical Oxygen Concepts Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.